Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Medicine (Baltimore) ; 94(39): e1554, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26426623

RESUMEN

Adult-onset Still's disease (AOSD) is often refractory to standard therapy. Anakinra (ANK), an interleukin-1 receptor antagonist, has demonstrated efficacy in single cases and small series of AOSD. We assessed the efficacy of ANK in a series of AOSD patients. Multicenter retrospective open-label study. ANK was used due to lack of efficacy to standard synthetic immunosuppressive drugs and in some cases also to at least 1 biologic agent. Forty-one patients (26 women/15 men) were recruited. They had a mean age of 34.4 ± 14 years and a median [interquartile range (IQR)] AOSD duration of 3.5 [2-6] years before ANK onset. At that time the most common clinical features were joint manifestations 87.8%, fever 78%, and cutaneous rash 58.5%. ANK yielded rapid and maintained clinical and laboratory improvement. After 1 year of therapy, the frequency of joint and cutaneous manifestations had decreased to 41.5% and to 7.3% respectively, fever from 78% to 14.6%, anemia from 56.1% to 9.8%, and lymphadenopathy from 26.8% to 4.9%. A dramatic improvement of laboratory parameters was also achieved. The median [IQR] prednisone dose was also reduced from 20 [11.3-47.5] mg/day at ANK onset to 5 [0-10] at 12 months. After a median [IQR] follow-up of 16 [5-50] months, the most important side effects were cutaneous manifestations (n = 8), mild leukopenia (n = 3), myopathy (n = 1), and infections (n = 5). ANK is associated with rapid and maintained clinical and laboratory improvement, even in nonresponders to other biologic agents. However, joint manifestations are more refractory than the systemic manifestations.


Asunto(s)
Inmunosupresores/uso terapéutico , Proteína Antagonista del Receptor de Interleucina 1/uso terapéutico , Enfermedad de Still del Adulto/tratamiento farmacológico , Adulto , Quimioterapia Combinada , Femenino , Humanos , Inmunosupresores/administración & dosificación , Proteína Antagonista del Receptor de Interleucina 1/administración & dosificación , Masculino , Persona de Mediana Edad , Prednisona/administración & dosificación , Estudios Retrospectivos
2.
Reumatol Clin ; 9(1): 38-41, 2013.
Artículo en Inglés, Español | MEDLINE | ID: mdl-23245639

RESUMEN

OBJECTIVE: To describe a large series of patients with mutilans/resorptive arthritis (AM) of a representative population of patients with psoriatic arthritis (PsA) and analyze the associated variables. METHODS: Multicenter cross-sectional study of consecutive patients affected by PsA in 8 centers. In patients with swelling or deformity of the hands or feet we performed an anteroposterior rx. The patient was affected by AM if erosive disorder affecting both articular surfaces completely was present. RESULTS: Of the 360 patients studied, 24 had PsA and AM (6.7%). The duration of their disease was significantly higher, and they exhibited a worse functional capacity as well as more DIP joint affection (P<.05). 30% had radiological changes indistinguishable from nodular osteoarthritis. CONCLUSIONS: AM in PA is associated with a worse functional capacity. Its possible association with nodular hand osteoarthritis deserves further study.


Asunto(s)
Artritis Psoriásica/fisiopatología , Resorción Ósea/etiología , Adulto , Anciano , Anciano de 80 o más Años , Artritis Psoriásica/diagnóstico por imagen , Resorción Ósea/diagnóstico por imagen , Estudios Transversales , Femenino , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Radiografía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...